Surveillance for Adverse Events After COVID-19 mRNA Vaccination.

ABSTRACT:

Importance

Safety surveillance of vaccines against COVID-19 is critical to ensure safety, maintain trust, and inform policy.

Objectives

To monitor 23 serious outcomes weekly, using comprehensive health records on a diverse population.

Design, setting, and participants

This study represents an interim analysis of safety surveillance data from Vaccine Safety Datalink. The 10 162 227 vaccine-eligible members of 8 participating US health plans were monitored with administrative data updated weekly and supplemented with medical record review for selected outcomes from December 14, 2020, through June 26, 2021.

Exposures

Receipt of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) COVID-19 vaccination, with a risk interval of 21 days for individuals after vaccine dose

SUBMITTER: Klein NP 

PROVIDER: S-EPMC8511971 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature